Patent intelligence · US
US 8507206
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)
Patent details — US 8507206
- Jurisdiction
- US
- Status
- granted
- Grant date
- Aug 13, 2013
- Expiration
- Aug 8, 2033
- Applicant
- Acumen Pharmaceuticals, Inc.
- Claims
- 1
- CPC classes
- A61P, A61P25/28
Quick answer
US 8507206 (Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Aug 13, 2013. Expires Aug 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Acumen Pharmaceuticals, Inc.
- Grant date
- Expiration
- Claims
- 1
- CPC classes
- A61P, A61P25/28
More from Acumen Pharmaceuticals, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 9320793
Method for treating a disease associated with soluble, oligomeric species of amyloid beta 1-42
granted -
US 9217024
ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
granted -
US 9006283
Methods of modifying amyloid β oligomers using non-peptidic compounds
granted -
US 8962677
Methods of restoring cognitive ability using non-peptidic compounds
granted -
US 7964359
Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
granted
Frequently asked questions
What is US patent 8507206?
US 8507206 (Monoclonal antibodies that target pathological assemblies of amyloid β (Abeta)) is held by Acumen Pharmaceuticals, Inc.. Status: granted. Granted Aug 13, 2013. Expires Aug 8, 2033 (7 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 8507206?
Acumen Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 6 pharmaceutical patents for this assignee.
When does US 8507206 expire?
Our index shows an expiration date of Aug 8, 2033 (7 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.